News Room

An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer Manufacturers frequently offer rebates that are passed through to consumers to reduce their

Trenton, February 14, 2022 ― “While we await the opportunity to review the actual bills that Governor Murphy proposed today, we look forward to working

An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer New Jersey’s research-based biopharmaceutical industry is constantly developing new cures and treatments that benefit

$350 billion goes to middlemen Trenton, January 11, 2022 ― An update to an important study demonstrates that pharmacy benefit managers (PBMs) and other middlemen

An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer and Christopher P. Molineaux, President and Chief Executive Officer of Life Sciences Pennsylvania